AdaptHealth Corp. 2022 Form 10-K Summary
Business context and reporting period
AdaptHealth provides healthcare-at-home solutions, including sleep therapy, diabetes devices and supplies, respiratory equipment, home medical equipment, oxygen therapy, and other chronic-care supplies. The company serviced approximately 3.9 million patients annually across all 50 states through approximately 725 locations in 47 states as of December 31, 2022. This Form 10-K covers the fiscal year ended December 31, 2022; the filing also reports fourth-quarter revenue, but does not provide a complete standalone fourth-quarter income statement.
Financial performance and key metrics
| Metric | FY 2022 | FY 2021 | Change |
|---|---|---|---|
| Net revenue | $2,970.6 million | $2,454.5 million | +21.0% |
| Operating income | $190.4 million | $225.6 million | -15.6% |
| Operating margin | 6.4% | 8.8% | -240 bps |
| Net income attributable to AdaptHealth | $69.3 million | $156.2 million | -55.6% |
| Net margin attributable to AdaptHealth | 2.4% | 6.0% | -360 bps |
| Adjusted EBITDA | $593.8 million | $565.9 million | +4.9% |
| Adjusted EBITDA margin | Approximately 20.0% | Approximately 23.1% | Declined |
| Net cash provided by operating activities | $373.9 million | $275.7 million | +35.6% |
| Free cash flow | $(17.6) million | $72.4 million | Declined |
Fourth-quarter 2022 net revenue was $780.3 million, compared with $702.1 million in the fourth quarter of 2021 and $756.5 million in the third quarter of 2022. Full-year revenue growth reflected approximately $439.8 million from acquisitions and $86.4 million of non-acquired growth, partly offset by a $10.1 million decline in business-to-business revenue.
- Point-in-time sales represented 67.9% of FY 2022 revenue; fixed monthly equipment reimbursements represented 32.1%.
- Sleep revenue was $1,066.7 million, or 35.9% of total revenue; diabetes revenue was $687.1 million, or 23.1%.
- Private third-party payors represented approximately 61% of revenue, while Medicare and Medicaid represented approximately 26%.
- Cost of net revenue increased 27.1% to $2,553.2 million, with the ratio rising to 85.9% of revenue from 81.8%. Product costs, labor, inflation, and patient-equipment depreciation were significant contributors.
- Interest expense increased 14.9% to $109.4 million because of higher average borrowings and higher interest rates.
Liquidity, debt, and capital allocation
- Cash and cash equivalents were $46.3 million at December 31, 2022, compared with $149.6 million at December 31, 2021.
- Long-term debt had $2.215 billion of principal outstanding, or $2.188 billion net of deferred financing costs. This included a $765.0 million secured term loan and $1.450 billion of senior unsecured notes.
- The secured term loan matures in January 2026; the senior notes mature in 2028, 2029, and 2030. The term loan carried an interest rate of 6.13% at year-end.
- The company had no revolver borrowings at year-end, $17.4 million of outstanding letters of credit, and approximately $432.6 million of revolver availability after letters of credit. The filing states that $25.0 million was subsequently borrowed under the revolver.
- Working capital was $129.1 million, down from $170.2 million.
- Capital expenditures were $391.4 million, primarily for patient medical equipment, causing negative free cash flow despite stronger operating cash flow.
- AdaptHealth repurchased $14.0 million of common stock, or 750,835 shares, during 2022. The board’s $200 million repurchase authorization had approximately $186 million remaining at year-end.
- Management stated that expected operating cash flow, existing cash, and available credit are expected to fund operations and growth strategies for at least the next twelve months.
Material changes versus the prior comparable period
- Revenue grew substantially, but profitability weakened as cost of net revenue increased faster than revenue and interest expense rose.
- Operating income fell $35.2 million and net income attributable to AdaptHealth fell $86.9 million, despite higher revenue and Adjusted EBITDA.
- Operating cash flow improved by $98.2 million, but equipment purchases increased by $188.1 million, turning free cash flow negative.
- Acquisition activity moderated sharply: 2022 acquisitions involved approximately $17.6 million of consideration versus approximately $2.9 billion in 2021, which included the AeroCare acquisition.
- The Philips Respironics recall continued to constrain ventilator, BiPAP, and CPAP device availability during 2022, although alternative sourcing improved relative to 2021.
- Medicare sequestration resumed at a 2% reduction for fee-for-service claims beginning July 1, 2022.
- The company implemented an enterprise resource planning system and continued remediation efforts related to internal controls, but the material weaknesses remained unresolved.
Outlook, commentary, risks, contingencies, and unusual items
The filing does not provide clear quantitative revenue, earnings, or Adjusted EBITDA guidance. Management emphasizes continued growth through acquisitions, non-acquired growth, technology-enabled operating efficiencies, and expansion of the company’s healthcare-at-home platform.
- Supply chain and Philips recall: Continued shortages, supplier concentration, labor constraints, shipping costs, and inflation may limit patient starts, raise costs, and pressure margins. The recall could also generate unrecoverable costs and litigation.
- Payor and reimbursement exposure: Private payor rate pressure, contract termination or renegotiation, Medicare and Medicaid policy changes, audits, documentation requirements, competitive bidding, and payment reductions could materially affect revenue and cash flow.
- Regulatory transition: The company expected the public health emergency and related waivers and flexibilities to end May 11, 2023, potentially increasing documentation and compliance requirements.
- Legal and investigative matters: The company disclosed ongoing government investigations relating to ventilator and oxygen billing, a securities class action, a shareholder derivative action, and other claims. Management reported no material accruals and believes adverse outcomes are not expected to be material, but stated that outcomes remain uncertain.
- Internal controls: Management concluded that disclosure controls and internal control over financial reporting were ineffective as of December 31, 2022 because of material weaknesses involving insufficient risk-assessment resources, process-level controls, and information-technology general controls. KPMG issued an adverse opinion on internal control effectiveness, while providing an unqualified opinion on the consolidated financial statements.
- Goodwill and intangible assets: Goodwill was $3.545 billion, representing a substantial portion of total assets. No impairment was recorded, but a sustained decline in market capitalization or operating performance could result in a material non-cash impairment charge.
- Tax Receivable Agreement: The company reported a $297.4 million TRA liability and may be required to pay former owners 85% of certain realized or deemed tax savings. Certain change-of-control or early-termination events could accelerate payments and adversely affect liquidity.
- COVID-19 assistance: CMS advance payments and deferred employment taxes were fully repaid by year-end. Previously recognized Provider Relief Fund income remains subject to ongoing reporting and potential recoupment if future guidance or audits determine that requirements were not satisfied.
Most important facts for investors to verify
- Whether supply constraints and the Philips recall continue to limit sleep and respiratory growth or generate additional costs.
- Whether revenue-cycle improvements and payor collections can support operating cash flow while patient-equipment capital spending remains elevated.
- Debt maturity, variable-rate exposure, covenant headroom, and the impact of higher interest rates before the January 2026 term-loan maturity.
- Progress and independent auditor conclusions regarding remediation of the material weaknesses in internal control over financial reporting.
- Status and potential exposure from the EDPA, WDKY, and Southern District of New York investigations, the securities class action, and the derivative action.
- Goodwill impairment sensitivity, including the effect of lower share price, reimbursement pressure, or weaker operating performance.
- Future Medicare and Medicaid reimbursement rates, sequestration, public-health-emergency rule changes, and private-payor contract actions.
- Potential cash payments under the Tax Receivable Agreement and any effect on acquisitions, repurchases, debt reduction, or liquidity.